Chart, page-974

There is nothing wrong with using past results to support a new study (all scientific studies do this), but the photos weren't really relevant to the latest study as they were from cell culture using a much higher dose of BIT225.

The constructive discussion here has centered around the importance of the latest phase 2 study and how likely BIT is to land a pharma deal. The current SP implies the market thinks a deal is likely so before you buy in (or not) you need to make your own investigations if you agree. I am skeptical, but I don't have a crystal ball only a lot of experience.